曲美他嗪对接受经皮冠状动脉介入治疗的2型糖尿病急性心肌梗死患者的疗效
本研究为随机对照研究,纳入2014年1月1日至2016年1月1日期间173例接受PCI的2型糖尿病急性心肌梗死患者,实验组89例、对照组84例,所有患者入院及住院期间接受阿司匹林和替格瑞洛。实验组入院给予曲美他嗪负荷剂量60mg,此后20mg每日三次。结果显示,与对照组相比,曲美他嗪组住院第2天CK和CK-MB显著降低,住院第1天和第6天cTNI显著降低,第6天ALT、AST和血糖显著降低,第10至14天LVEF显著升高;Cr、血清尿素、LA、LVEDD和CO无显著差异。
要点
- 在2型糖尿病AMI接受PCI患者中,曲美他嗪组住院第2天CK为797±582 vs 对照组1092±1114(p=0.029),CK-MB为80±60 vs 105±100(p=0.041)。
- 曲美他嗪组住院第1天cTNI为13.5±12.7 vs 对照组19.8±19.2,第6天为3.3±3.2 vs 4.8±4.7(双侧p=0.012)。
- 曲美他嗪组第6天ALT为29.0±11.6 vs 对照组42.4±24.5,AST为39.8±17.3 vs 69.2±70.0(双侧p=0.000)。
- 曲美他嗪组第6天空腹血糖为6.80±2.12 vs 对照组7.59±2.24(p=0.019),第10至14天LVEF为58.4±8.6 vs 54.9±8.4(p=0.008)。
- Cr、血清尿素、LA、LVEDD和CO两组无显著差异(p=0.988、p=0.569、p=0.264、p=0.128、p=0.929)。
适用人群与场景
- 2型糖尿病合并急性心肌梗死并接受经皮冠状动脉介入治疗的患者,年龄等基线特征原文未报告。
- 所有患者入院时及住院期间均接受阿司匹林和替格瑞洛治疗。
处置流程与药物剂量
- 实验组:入院时给予曲美他嗪负荷剂量60mg,此后20mg每日三次。
- 所有患者入院时及住院期间接受阿司匹林和替格瑞洛。
- 所有患者均接受经皮冠状动脉介入治疗。
研究设计与关键结果
- 研究类型:随机对照研究;样本量173例(实验组89例,对照组84例);人群为2014年1月1日至2016年1月1日期间接受PCI的2型糖尿病急性心肌梗死患者。
- 干预:实验组入院给予曲美他嗪负荷60mg,此后20mg每日三次;对照组未接受曲美他嗪;所有患者均接受阿司匹林、替格瑞洛和PCI。
- 主要终点(心肌酶):实验组住院第2天CK为797±582 vs 对照组1092±1114(p=0.029),CK-MB为80±60 vs 105±100(p=0.041);cTNI住院第1天为13.5±12.7 vs 19.8±19.2,住院第6天为3.3±3.2 vs 4.8±4.7(双侧p=0.012)。
- 次要终点(肝功能、血糖、心功能):实验组第6天ALT为29.0±11.6 vs 对照组42.4±24.5,AST为39.8±17.3 vs 69.2±70.0(双侧p=0.000);第6天血糖为6.80±2.12 vs 7.59±2.24(p=0.019);第10至14天LVEF为58.4±8.6 vs 54.9±8.4(p=0.008)。
- 无显著差异的终点:Cr(p=0.988)、血清尿素(p=0.569)、LA(36.3±4.5 vs 37.0±4.1,p=0.264)、LVEDD(52.0±4.9 vs 53.1±4.6,p=0.128)、CO(5.4±0.9 vs 5.4±0.9,p=0.929)。
证据类型、等级与局限
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于2型糖尿病急性心肌梗死接受PCI的患者,作者认为曲美他嗪(入院负荷60mg,此后20mg每日三次)可显著降低血清心肌酶、改善肝功能、调节血糖并改善心脏功能。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Trimetazidine (TMZ) improves clinical outcomes in patients with chronic heart failure and stable coronary artery disease. No study has yet evaluated the efficacy of TMZ in type 2 diabetes patients with acute myocardial infarction (AMI) undergoing Percutaneous Coronary Intervention (PCI). We performed this study to evaluate the efficacy TMZ in DM patients with AMI undergoing PCI, such as the effect on reductions in myocardial enzyme, improvements in liver function, modulation of glucose levels, and improvement in cardiac function.
METHODS: For this randomized study, we enrolled 173 AMI patients with type 2 diabetes undergoing PCI between January 1, 2014, and January 1, 2016. All patients received aspirin and ticagrelor upon admission and throughout their hospitalization. Patients in the experimental group were treated with a loading dose of 60mg TMZ at admission, and 20 mg TMZ three times a day thereafter. 89 patients were included in experimental group, and 84 patients were included in control group. All patients received PCI treatments. The endpoints evaluated were serum creatine kinase and its isoenzyme (CK and CK-MB), cardiac troponin I (cTNI), serum creatinine (Cr), serum urea, blood glucose, serum glutamic pyruvic transaminase (ALT), serum glutamic oxaloacetictransaminase (AST), left atrial dimension (LA), left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD), and cardiac output (CO).
FINDINGS: Compared with the control group, TMZ treatment significantly reduced CK and CK-MB on the second day in hospital ([797±582] vs. [1092±1114]; [80±60] vs. [105±100]; p=0.029, p=0.041, respectively), and cTNI after one and six days in hospital ([13.5±12.7] vs. [19.8±19.2]; [3.3±3.2] vs. [4.8±4.7]; two-tailed p=0.012). In addition, TMZ significantly lowered liver enzymes (ALT, AST) at 6days ([29.0±11.6] vs. [42.4±24.5]; [39.8±17.3] vs. [69.2±70.0]; two-tailed p=0.000), lowered glucose after 6days ([6.80±2.12] vs. [7.59±2.24]; p=0.019), and increased LVEF after ten to fourteen days ([58.4±8.6] vs. [54.9±8.4]; p=0.008). There were no significant effect on Cr and serum urea (p=0.988, p=0.569, respectively), nor on LA, LVEDD, and CO ([36.3±4.5] vs. [37.0±4.1], p=0.264; [52.0±4.9] vs. [53.1±4.6], p=0.128; [5.4±0.9] vs. [5.4±0.9], p=0.929, respectively).
IMPLICATIONS: Among type 2 diabetic patients with AMI undergoing PCI, TMZ significantly reduces serum myocardial enzyme, improves liver function, adjusts blood glucose and improves cardiac function.
参考来源
- Li R, Tang X, Jing Q, et al. The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI. Am J Emerg Med. 2017. PMID: 28587952. doi:10.1016/j.ajem.2017.05.024
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。